First AD

Second AD

Panelists discuss their clinical experiences with Janus kinase (JAK) inhibitors for treating alopecia, noting observed differences in outcomes and tolerability among various systemic JAK inhibitors, while highlighting the advantages of these therapies over traditional local and systemic treatment options.

Real-World Clinical Experience With JAK Inhibitors

Video content above is prompted by the following:

What has been your clinical experience with JAK inhibitors for treatment of alopecia?

    a. Have you observed differences in outcomes and/or tolerability with using   different systemic JAK inhibitors?

What are the advantages of using systemic JAK inhibitor therapies compared with traditional local or systemic therapies?

Recent Advances in the Treatment of Alopecia Areata

Medcast Videos

Recent Advances in Treatment of Alopecia Areata

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

JAK inhibitors have shown promise in treating alopecia, offering a novel approach compared to traditional therapies. Clinicians have observed varying outcomes and tolerability among different systemic JAK inhibitors, with some patients responding better to specific agents. Systemic JAK inhibitors provide advantages over traditional therapies, including more targeted action and potential for improved efficacy in severe cases. However, considerations regarding side effects and long-term safety remain crucial. The choice of JAK inhibitor may depend on individual patient factors, including previous treatment responses and specific alopecia subtype.